Trials / Not Yet Recruiting
Not Yet RecruitingNCT07133802
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine in Adults Aged 18-59 Years
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6,680 (estimated)
- Sponsor
- Changchun BCHT Biotechnology Co. · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo Group | Each human dose: 0.2 mL |
| BIOLOGICAL | Test Group | Each human dose is 0.2 mL |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2026-03-01
- Completion
- 2026-07-01
- First posted
- 2025-08-21
- Last updated
- 2025-08-21
Source: ClinicalTrials.gov record NCT07133802. Inclusion in this directory is not an endorsement.